News >

Management of Newly Diagnosed mCRC Driven by Molecular Markers

Caroline Seymour
Published: Tuesday, Jun 11, 2019

Wells A. Messersmith, MD

Wells A. Messersmith, MD

The average survival of patients with metastatic colorectal cancer (mCRC) hovers around 3 years, but by understanding where the tumor originated and the increasing array of molecular markers, clinicians have a better chance of optimizing outcomes, explained Wells A. Messersmith, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication